Riding the growth of its HIV franchise, Gilead Sciences Inc. reported solid earnings for the third quarter, beating consensus estimates by a penny. (Bioworld Today)

Riding the growth of its HIV franchise, Gilead Sciences Inc. reported solid earnings for the third quarter, beating consensus estimates by a penny. (Bioworld Today)